Compare FUBO & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUBO | EYPT |
|---|---|---|
| Founded | 2009 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2020 | 2005 |
| Metric | FUBO | EYPT |
|---|---|---|
| Price | $2.71 | $17.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $5.35 | ★ $29.60 |
| AVG Volume (30 Days) | ★ 10.3M | 1.3M |
| Earning Date | 11-03-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $1,616,726,000.00 | $42,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.99 | N/A |
| P/E Ratio | $7.99 | ★ N/A |
| Revenue Growth | ★ 1.70 | N/A |
| 52 Week Low | $1.21 | $3.91 |
| 52 Week High | $6.45 | $19.11 |
| Indicator | FUBO | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 35.57 | 66.36 |
| Support Level | $2.55 | $16.52 |
| Resistance Level | $2.76 | $17.40 |
| Average True Range (ATR) | 0.11 | 1.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 37.80 | 71.27 |
FuboTV Inc is a sports-first, live TV streaming company offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, FuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. It offers subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality suited to their preferences. The company has one operating segment, the streaming business. Geographically, the company generates a majority of its revenue from the United States and also has a presence in other markets.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.